A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Inclusion Criteria:

- The subject's parent(s)/legal guardian(s) understand(s) and voluntarily signed an
informed consent document prior to any study-related assessments/procedures being
conducted. Where locally applicable, the subject also understands and voluntarily
provides his/her assent prior to any study-related assessments/procedures being
conducted

- Subject has been diagnosed with melanoma, rhabdomyosarcoma, or other tumor where tumor
resection or biopsy is planned and lymph node mapping is appropriate

- The subject is clinically node negative (cN0) at the time of screening

- Age < 18 years

- Male subjects of childbearing potential must be willing to use a condom during sexual
intercourse and shall not father a child during the course of the study or will
practice complete abstinence while on study

- Female subjects of childbearing potential must agree to the use of two
physician-approved contraceptive methods simultaneously or practice complete
abstinence while on study

Exclusion Criteria:

- The subject has had preoperative radiation therapy

- Has had previous surgery or radiation to node basins that would be involved in the
intraoperative lymph node mapping (ILM) procedure

- Has a known allergy to dextran or VBD (if intended to be used)

- Has a history of alcohol abuse or alcohol dependency in the 3 years before study
entry, or is an alcoholic or drug addict, as determined by the investigator

- Before the administration of Lymphoseek, has received any radiopharmaceutical within 7
radioactive half-lives of that radiopharmaceutical